Mike Haney: So I just want to push on this a little bit more because again I think this is where the sort of popular perspective is
Reduced cerebral insulin sensitivity disrupts the neural controlling food intake
Cycle Strategies For AOD-9604 Peptide AOD9604 is typically run in short cycles rather than continuous year-round use: Cycle Length: 412 weeks, depending on body composition goals Break Periods: Taking 24 weeks off between cycles may help maintain sensitivity and responsiveness Expected Results: Clinical data shows reductions in fat mass may start appearing after 68 weeks of consistent use, but results vary based on diet, training, and metabolic health (trial overview) Stacking AOD9604 with Other Peptides or Supplements Many athletes and clinics stack AOD9604 with other compounds to enhance its fat-burning potential: CJC1295 + Ipamorelin Promotes growth hormone release, potentially amplifying fat-loss effects
This article examines the current evidence, biological mechanisms, and clinical implications of GLP-1 receptor agonists in relation to cognitive function and dementia risk
The two most notorious culprits are Proton Pump Inhibitors (PPIs) , used for acid reflux, and Metformin , the first-line treatment for Type 2 diabetes
Since GLP-1 prescription drugs were approved for use to address health conditions outside of diabetes in 2021, several drugs have become available to Americans looking to improve their health and lose weight